Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-17 20:41 | 2026-06-16 | IRWD | IRONWOOD PHARMACEUTICALS INC | McHugh Julie | Director | SELL | $3.73 | 21,571 | $80,460 | 250,749 |
| 2026-06-17 20:42 | 2026-06-15 | CMND | Clearmind Medicine Inc. | HRT FINANCIAL LP | 10% owner | SELL | $3.32 | 3,183 | $10,568 | 103,492 |
| 2026-06-17 20:45 | 2026-06-15 | BBIO | BridgeBio Pharma, Inc. | Cook Jennifer E. | Director | OPT+S | $66.62 | 90,240 | $6,012,159 | 6,589 |
| 2026-06-17 20:45 | 2026-06-15 | JAZZ | Jazz Pharmaceuticals plc | Smith Mark Douglas | Director | SELL | $230.55 | 1,157 | $266,746 | 9,680 |
| 2026-06-17 20:01 | 2026-06-15 | XNCR | Xencor Inc | Montgomery Alan Bruce | Director | SELL | $12.31 | 5,064 | $62,338 | 15,547 |
| 2026-06-17 20:01 | 2026-06-15 | XNCR | Xencor Inc | RANIERI RICHARD J | Director | SELL | $12.31 | 5,474 | $67,385 | 13,709 |
| 2026-06-17 20:01 | 2026-06-15 | XNCR | Xencor Inc | GUSTAFSON KURT A | Director | SELL | $12.31 | 5,474 | $67,385 | 14,709 |
| 2026-06-17 20:01 | 2026-06-15 | ARDX | ARDELYX, INC. | RAAB MICHAEL | Director, Officer | OPT+S | $5.67 | 41,666 | $236,346 | 1,699,200 |
| 2026-06-17 20:02 | 2026-06-15 | XNCR | Xencor Inc | GORMAN KEVIN CHARLES | Director | SELL | $12.31 | 7,527 | $92,657 | 11,378 |
| 2026-06-17 15:21 | 2026-06-16 | ANIX | Anixa Biosciences Inc | Titterton Lewis H jr | Director | BUY | $2.64 | 2,836 | $7,487 | 972,170 |
| 2026-06-17 10:03 | 2026-06-16 | BLTE | BELITE BIO, INC | Scholl Hendrik Peter | Officer | SELL | $140.57 | 10,000 | $1,405,729 | 25,000 |
| 2026-06-16 20:22 | 2026-06-15 | PCSA | Processa Pharmaceuticals, Inc. | Ng George K | Director, Officer | BUY | $2.22 | 2,465 | $5,472 | 12,435 |
| 2026-06-16 20:21 | 2026-06-15 | PCSA | Processa Pharmaceuticals, Inc. | Lin Patrick | Officer | BUY | $2.22 | 1,831 | $4,065 | 11,007 |
| 2026-06-16 20:20 | 2026-06-15 | PCSA | Processa Pharmaceuticals, Inc. | Guy Wendy | Officer | BUY | $2.22 | 2,118 | $4,702 | 11,958 |
| 2026-06-16 20:09 | 2026-06-15 | AQST | Aquestive Therapeutics, Inc. | Barber Daniel | Officer | SELL | $4.16 | 25,000 | $104,010 | 635,574 |
| 2026-06-16 20:24 | 2026-06-15 | PCSA | Processa Pharmaceuticals, Inc. | Young David | Director, Officer | BUY | $2.22 | 2,067 | $4,589 | 19,198 |
| 2026-06-16 20:23 | 2026-06-15 | PCSA | Processa Pharmaceuticals, Inc. | SKIBSTED RUSSELL | Officer | BUY | $2.22 | 2,654 | $5,892 | 13,412 |
| 2026-06-16 20:35 | 2026-06-15 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $549.17 | 10,000 | $5,491,742 | 18,876 |
| 2026-06-16 20:36 | 2026-06-15 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $549.15 | 9,500 | $5,216,917 | 40,513 |
| 2026-06-17 00:31 | 2026-06-12 | SEPN | Septerna, Inc. | Shaikhly Samira | Officer | OPT+S | $35.08 | 6,250 | $219,224 | 793 |
| 2026-06-16 22:19 | 2026-06-12 | PBLS | Parabilis Medicines, Inc. | SEBULSKY ALAN | Director | BUY | $27.06 | 17,500 | $473,529 | 30,000 |
| 2026-06-16 22:01 | 2026-06-12 | HOWL | Werewolf Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% owner | SELL | $0.39 | 448,836 | $173,744 | 331,414 |
| 2026-06-16 21:26 | 2026-06-15 | IONS | IONIS PHARMACEUTICALS INC | BERTHELSEN SPENCER R | Director | OPT+S | $73.49 | 8,000 | $587,920 | 156,013 |
| 2026-06-16 21:26 | 2026-06-12 | IONS | IONIS PHARMACEUTICALS INC | Kordasiewicz Holly B. | Officer | OPT+S | $73.41 | 60,846 | $4,466,425 | 22,458 |
| 2026-06-16 20:42 | 2026-06-12 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Director | OPT+S | $50.00 | 4,500 | $225,000 | 41,500 |
| 2026-06-16 20:46 | 2026-06-12 | TVTX | Travere Therapeutics, Inc. | Coughlin Timothy | Director | OPT+S | $50.07 | 10,000 | $500,747 | 56,250 |
| 2026-06-16 20:30 | 2026-06-12 | LQDA | Liquidia Corp | Bloch Stephen M | Director | SELL | $71.45 | 196,111 | $14,012,582 | 980,073 |
| 2026-06-16 20:15 | 2026-06-15 | IMRX | Immuneering Corp | Hall Brett Matthew | Officer | BUY | $4.15 | 6,035 | $25,045 | 382,531 |
| 2026-06-16 20:15 | 2026-06-16 | DRMA | Dermata Therapeutics, Inc. | Scott Kathleen D. | Director | SELL | $1.19 | 11 | $13 | 0 |
| 2026-06-16 13:14 | 2026-06-12 | ADTX | Aditxt, Inc. | HRT FINANCIAL LP | 10% owner | BUY | $0.02 | 4,252,767 | $68,044 | 2,459,308 |
| 2026-06-16 13:19 | 2026-06-12 | CMND | Clearmind Medicine Inc. | HRT FINANCIAL LP | 10% owner | SELL | $3.36 | 2,102 | $7,063 | 106,675 |
| 2026-06-16 13:00 | 2026-06-12 | ANIX | Anixa Biosciences Inc | KUMAR AMIT | Director, Officer | BUY | $2.50 | 21,000 | $52,500 | 630,812 |
| 2026-06-16 12:28 | 2026-06-11 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Kalif Eliyahu Sharon | Officer | SELL | $34.10 | 106,563 | $3,633,308 | 65,621 |
| 2026-06-15 20:50 | 2026-06-12 | SXTP | 60 DEGREES PHARMACEUTICALS, INC. | DOW GEOFFREY S | Director, Officer | BUY | $1.38 | 7,350 | $10,131 | 24,131 |
| 2026-06-15 20:36 | 2026-06-12 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $541.39 | 9,500 | $5,143,215 | 40,513 |
| 2026-06-16 01:06 | 2026-06-12 | LGND | LIGAND PHARMACEUTICALS INC | Haas Jason | Director | OPT+S | $255.58 | 6,461 | $1,651,320 | 4,981 |
| 2026-06-16 00:58 | 2026-06-11 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | Director, Officer, 10% owner | SELL | $3.88 | 18,124 | $70,352 | 132,715 |
| 2026-06-16 00:07 | 2026-06-11 | ADTX | Aditxt, Inc. | BANK OF AMERICA CORP /DE/ | 10% owner | SELL | $0.01 | 15 | $0 | 49 |
| 2026-06-16 00:07 | 2026-06-11 | ADTX | Aditxt, Inc. | BANK OF AMERICA CORP /DE/ | 10% owner | BUY | $0.01 | 7 | $0 | 64 |
| 2026-06-16 00:09 | 2026-06-12 | PBYI | PUMA BIOTECHNOLOGY, INC. | Dorval Allison | Director | SELL | $7.20 | 11,610 | $83,579 | 90,780 |
| 2026-06-16 00:10 | 2026-06-12 | PBYI | PUMA BIOTECHNOLOGY, INC. | MOYES JAY M | Director | SELL | $7.22 | 22,000 | $158,796 | 58,322 |
| 2026-06-16 00:13 | 2026-06-12 | PBYI | PUMA BIOTECHNOLOGY, INC. | Senderowicz Adrian | Director | SELL | $7.20 | 27,000 | $194,311 | 27,000 |
| 2026-06-16 00:14 | 2026-06-12 | PBYI | PUMA BIOTECHNOLOGY, INC. | Stuglik Brian M | Director | SELL | $7.20 | 8,100 | $58,311 | 113,858 |
| 2026-06-16 00:16 | 2026-06-12 | PBYI | PUMA BIOTECHNOLOGY, INC. | WILSON TROY EDWARD | Director | SELL | $7.20 | 10,800 | $77,748 | 59,750 |
| 2026-06-15 23:48 | 2026-06-15 | ABEO | ABEONA THERAPEUTICS INC. | Silverstein Christine Berni | Director | SELL | $5.71 | 18,160 | $103,695 | 119,562 |
| 2026-06-15 22:50 | 2026-06-15 | ORKA | Oruka Therapeutics, Inc. | Quinlan Paul T | Officer | SELL | $69.69 | 733 | $51,083 | 31,034 |
| 2026-06-15 22:50 | 2026-06-15 | RARE | Ultragenyx Pharmaceutical Inc. | Sanders Corazon (Corsee) D. | Director | SELL | $25.05 | 2,000 | $50,100 | 21,095 |
| 2026-06-15 22:51 | 2026-06-15 | ORKA | Oruka Therapeutics, Inc. | Sandler Laura Lee | Officer | SELL | $69.69 | 600 | $41,814 | 236,384 |
| 2026-06-15 22:52 | 2026-06-15 | ORKA | Oruka Therapeutics, Inc. | Klein Lawrence Otto | Director, Officer | SELL | $69.69 | 1,729 | $120,494 | 925,580 |
| 2026-06-15 22:54 | 2026-06-15 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Officer | OPT+S | $69.28 | 7,947 | $550,607 | 32,718 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.